Endostar Combined TACE Different Regimens In Patients With Advanced Hepatocellular Carcinoma Serum VEGF Expression Comparative Analysis

Objective: Discussion Endostar combined TACE different regimens in patients with advanced hepatocellular carcinoma serum VEGF expression were analyzed.Metheods: Select both liver pathology or biopsy results confirmed the clinical diagnostic criteria consistent with hepatocellular carcinoma in patients with advanced hepatocellular carcinoma in 60 cases, 60 patients were randomly divided into two groups, A group, the control group, 30 cases(recombinant human endostatin combined with transcatheter arterial chemoembolization arterial infusion group); group B, the study group, 30 cases(recombinant human endostatin combined with transcatheter arterial chemoembolization and postoperative arterial infusion group). A group(control group): First surgery catheter select target blood supply to the tumor lesion artery infusion therapy, slowly push the syringe infusion of recombinant human endostatin 15 mg, 50 mg oxaliplatin and epirubicin hydrochloride injection doxorubicin 30 mg, then the recombinant human endostatin 15 mg and 5 ~ 15 ml super liquid iodized oil(amount according to lesion size) by T-piece rotary valve fully emulsified slowly after embolization of tumor lesions in perspective and target blood vessels. Group B(the study group): surgical approach and chemoembolization drug selection with the A group, and in the first days after the start of infusion of recombinant human endostatin, continuous infusion for 7 days, Usage: 30 mg recombinant human endostatin 500ml0.9% Na Cl was added slowly intravenously. The whole group of 60 patients, respectively, in one day before surgery, 3 days, 7 days, 15 days, 30 days each fasting blood 3ml, 60 patients serum vascular endothelial growth factor by enzyme-linked immunosorbent assay( VEGF) expression levels and statistical analysis, follow-up record postoperative complications were observed.Results: 1. The enzyme-linked immunosorbent assay(ELISA) test results show: A, two groups of patients before surgery one day B serum vascular endothelialgrowth factor(VEGF) expression levels compared with no significant difference(P> 0.05). A, B two groups of patients after the third day of serum vascular endothelial growth factor(VEGF) levels are increased and reached the highest value, seven days after surgery, 15 days, 30 days of serum vascular endothelial growth factor(VEGF) expression levels continued slow performance and reduce levels were lower than the preoperative and postoperative A, B groups each period of serum vascular endothelial growth factor(VEGF) expression levels before surgery compared with the significant difference(P <0.05). ANOVA results are shown: A, B postoperative periods each serum vascular endothelial growth factor(VEGF) expression levels compared to the significant difference(P <0.05) and the research group of vascular endothelial growth factor(VEGF) expression level was significantly lower than the control groups.2. The recombinant human endostatin Complications: A, group B was a transient increase in transaminases, mild jaundice, nausea, vomiting and other transcatheter arterial chemoembolization embolization syndrome, A, group B each There are three cases of patients with chest discomfort, but no ECG changes, the two groups were not found in nasal bleeding, arrhythmias and other adverse reactions. Two groups of patients recombinant human endostatin-related complications occurred no significant difference(P> 0.05).Conclusion: 1. Endostar combined with TACE can significantly reduce serum levels of VEGF.2. Endostar combined TACE and after intravenous administration more simple way Endostar combined TACE artery embolization is superior.